• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Shih Alvin

    2/2/24 8:08:38 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Shih Alvin

    (Last) (First) (Middle)
    C/O ZEVRA THERAPEUTICS, INC.
    1180 CELEBRATION BOULEVARD, SUITE 103

    (Street)
    CELEBRATION FL 34747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ZEVRA THERAPEUTICS, INC. [ ZVRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/20/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $5.72(1) 01/20/2024 A 58,800 (2) 01/19/2034 Common Stock 58,800 $0 58,800 D
    Explanation of Responses:
    1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, January 19, 2024.
    2. Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 33.33% of the shares will vest on January 20, 2025 and the remaining 66.67% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
    /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Alvin Shih 02/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KMPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KMPH

    DatePrice TargetRatingAnalyst
    11/17/2022$20.00Overweight
    Cantor Fitzgerald
    9/15/2022$20.00Buy
    Canaccord Genuity
    1/31/2022$10.00 → $11.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $KMPH
    SEC Filings

    See more
    • SEC Form S-3 filed by KemPharm Inc.

      S-3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      2/2/24 9:39:30 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Inc. filed SEC Form 8-K: Leadership Update

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      1/23/24 7:37:15 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      1/8/24 8:03:19 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zevra Therapeutics Begins Trading as ZVRA

      Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwa

      3/1/23 7:43:50 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

      CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people. NORD is dedicated to promoting research and access to therapies for the more than 300 million people worldwide with rare disea

      2/28/23 8:00:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

      CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's 2023 Annual Meeting of Stockholders ("Annual Meeting"), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company's Annual Meeting — Richard W. Pascoe, David S. Tier

      2/27/23 4:30:03 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Schafer Joshua

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 9:22:49 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sangiovanni Timothy J.

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 8:17:46 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mickle Christal M M

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 8:14:52 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care